BergenBio Fundamentale Forhold (BGBIO)

[Timm]

“BerGenBio AS has an analyst consensus of Moderate Buy, with a price target consensus of $6.17.” Skulle bety vel rundt 60 kroner det nå…

https://www.analystratings.com/articles/bergenbio-as-brrgf-gets-a-buy-rating-from-h-c-wainwright/

[Albinoen]

470m NOK in cash, MCAP 920m NOK = pipeline value is 450m NOK!!! The lowest P/B to date despite decreasing pipeline risk! If you know any other nordic biotech company with such low P/B and strong pipeline headlines - let me know!?

[TekBot]

BerGenBio ASA: Last day of subscription period in the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG
SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR
…

Vis børsmeldingen

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT
THE END OF THE PRESS RELEASE

Bergen, 12 March 2020: Reference is made to the stock exchange announcement from
BerGenBio ASA (the “Company”) dated 26 February 2020 relating to the subsequent
offering and listing of up to 1,500,000 new shares, each with a nominal value of
NOK 0.10 (the Offer Shares") at a subscription price of NOK 18.00 per Offer
Share (the Subscription Price") to be carried out by the Company (the
“Subsequent Offering”).

The subscription period for the Subsequent Offering will expire today, 12 March
2020, at 16:30 hours (CET). Correctly completed subscription forms must be
received by one of the subscription offices, or, in the case of online
subscriptions, be registered, within this deadline.

Please note that subscription rights that are not used to subscribe for Offer
Shares within the deadline will have no value and will lapse without
compensation to the holder

For more information regarding the Subsequent Offering, please refer to the
prospectus of the Company dated 26 February 2020 (the “Prospectus”). The
Prospectus, including the subscription form, is, subject to applicable law,
available at the following websites: www.bergenbio.com. Also, printed copies of
the prospectus may be obtained at the offices of BerGenBio ASA, Jonas Lies vei
91, 5009 Bergen, Norway or by contacting the Managers (defined below).

Arctic Securities AS and Carnegie AS (together the “Managers”) are acting as
Joint Bookrunners and Managers for the Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as the Company’s legal adviser for the
Subsequent Offering.

---

For further information, please contact:

Richard Godfrey, CEO BerGenBio ASA

richard.godfrey@bergenbio.com

+47 917 86 304

Rune Skeie, CFO BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer and
leukaemia. A first-in-class functional blocking AXL antibody, tilvestamab
(BGB149), and an AXL-ADC (ADCT-601) are undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify those
patient populations most likely to benefit from bemcentinib: this is expected to
facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com

• IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities laws of any
jurisdiction.

This communication may not be published, distributed or transmitted in or into
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People’s Republic of China, South Africa or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States of America or to U.S. persons (as defined in the U.S.
Securities Act of 1933, as amended (the “Securities Act”)) or to publications
with a general circulation in the United States of America. This document is not
an offer for sale of securities in the United States. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under
Securities Act. BerGenBio does not intend to register any part of the offering
in the United States. There will be no public offering of the securities in the
United States of America.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to
this communication in any member state of the European Economic Area (each an
“EEA Member State”) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable implementing
measures in any Member State, the “Prospectus Directive”) is only addressed to
qualified investors in that Member State within the meaning of the Prospectus
Directive. This announcement is not a prospectus within the meaning of the
Prospectus Directive, as implemented in each member State of the European
Economic Area. With respect to the EEA Member States, no action has been
undertaken or will be undertaken to make an offer to the public of the
securities referred to herein requiring a publication of a prospectus in any
Member State. As a result, the securities of the Company may not and will not be
offered in any Member State except in accordance with the exemptions set forth
in Article 3 of the Prospectus Directive.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of BerGenBio and those
explicitly or implicitly presumed in these statements. Against the background of
these uncertainties, readers should not rely on forward-looking statements.
BerGenBio assumes no responsibility to update forward -looking statements or to
adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA: Results of the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG
SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR
…

Vis børsmeldingen

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT
THE END OF THE PRESS RELEASE

Bergen, 12 March 2020: Reference is made to the stock exchange announcement from
BerGenBio ASA (the “Company”) dated 26 February 2020 relating to the subsequent
offering and listing of up to 1,500,000 new shares, each with a nominal value of
NOK 0.10 (the Offer Shares") at a subscription price of NOK 18.00 per Offer
Share (the Subscription Price") to be carried out by the Company (the
“Subsequent Offering”).

The subscription period for the Subsequent Offering expired today, 12 March
2020, at 16:30 hours (CET). At the expiry of the subscription period the Company
has received subscriptions for 9,087 Offer Shares from shareholders in the
Subsequent Offering.

The final allocation of the Offer Shares will be resolved in accordance with the
allocation criteria set out in the prospectus dated 26 February 2020. The final
results of the Subsequent Offering will be published shortly thereafter, and
letters regarding allocation of Offer Shares and the corresponding subscription
amount to be paid by each eligible shareholder who has subscribed for Offer
Shares in the Subsequent Offering, will be distributed during the course of
tomorrow, 13 March 2020.

Arctic Securities AS and Carnegie AS (together the “Managers”) are acting as
Joint Bookrunners and Managers for the Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as the Company’s legal adviser for the
Subsequent Offering.

---

For further information, please contact:

Richard Godfrey, CEO BerGenBio ASA

richard.godfrey@bergenbio.com

+47 917 86 304

Rune Skeie, CFO BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer and
leukaemia. A first-in-class functional blocking AXL antibody, tilvestamab
(BGB149), and an AXL-ADC (ADCT-601) are undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify those
patient populations most likely to benefit from bemcentinib: this is expected to
facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com

• IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities laws of any
jurisdiction.

This communication may not be published, distributed or transmitted in or into
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People’s Republic of China, South Africa or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States of America or to U.S. persons (as defined in the U.S.
Securities Act of 1933, as amended (the “Securities Act”)) or to publications
with a general circulation in the United States of America. This document is not
an offer for sale of securities in the United States. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under
Securities Act. BerGenBio does not intend to register any part of the offering
in the United States. There will be no public offering of the securities in the
United States of America.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to
this communication in any member state of the European Economic Area (each an
“EEA Member State”) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable implementing
measures in any Member State, the “Prospectus Directive”) is only addressed to
qualified investors in that Member State within the meaning of the Prospectus
Directive. This announcement is not a prospectus within the meaning of the
Prospectus Directive, as implemented in each member State of the European
Economic Area. With respect to the EEA Member States, no action has been
undertaken or will be undertaken to make an offer to the public of the
securities referred to herein requiring a publication of a prospectus in any
Member State. As a result, the securities of the Company may not and will not be
offered in any Member State except in accordance with the exemptions set forth
in Article 3 of the Prospectus Directive.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of BerGenBio and those
explicitly or implicitly presumed in these statements. Against the background of
these uncertainties, readers should not rely on forward-looking statements.
BerGenBio assumes no responsibility to update forward -looking statements or to
adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Nocturne]

Eh… Det var faktisk noen som tegnet seg i denne emisjonen? Helt seriøst? Hva er det jeg ikke skjønner?

[coyw]

bare 35% i minus da. Bedre enn mange av oss for tiden

[larslars]

Veldedighet? Støtte et godt formål??

[TekBot]

BerGenBio ASA: Final results of the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG
SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR
…

Vis børsmeldingen

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT
THE END OF THE PRESS RELEASE

Bergen, 13 March 2020: Reference is made to the stock exchange announcement from
BerGenBio ASA (the “Company”) dated 26 February 2020 relating to the subsequent
offering and listing of up to 1,500,000 new shares, each with a nominal value of
NOK 0.10 (the Offer Shares") at a subscription price of NOK 18.00 per Offer
Share (the Subscription Price") to be carried out by the Company (the
“Subsequent Offering”).

The subscription period in the Subsequent Offering expired on 12 March 2020, at
16:30 hours (CET). By the end of the subscription period, the Company had
received valid subscription for 6,397 Offer Shares. A total of 3,689 Offer
Shares will be allocated based on subscription rights and a total of 2,708 Offer
Shares will be allocated based on over-subscription in accordance with the
allocation criteria set out in the prospectus dated 26 February 2020.

Notifications of allocated Offer Shares in the Subsequent Offering and the
corresponding amount to be paid by each subscriber will be sent out in a
separate letter to each subscriber. Allocation letters will be sent out on 13
March 2020.

Subject to timely payment of the entire subscription amount in the Subsequent
Offering, the share capital increase relating to the Subsequent Offering is
expected to be registered with the Norwegian Register of Business Enterprises on
or about 23 March 2020 and the Offer Shares will be delivered to the VPS
accounts of the subscribers to whom they are allocated on or about 24 March
2020.

Arctic Securities AS and Carnegie AS (together the “Managers”) are acting as
Joint Bookrunners and Managers for the Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as the Company’s legal adviser for the
Subsequent Offering.

---

For further information, please contact:

Richard Godfrey, CEO BerGenBio ASA

richard.godfrey@bergenbio.com

+47 917 86 304

Rune Skeie, CFO BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer and
leukaemia. A first-in-class functional blocking AXL antibody, tilvestamab
(BGB149), and an AXL-ADC (ADCT-601) are undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify those
patient populations most likely to benefit from bemcentinib: this is expected to
facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com

• IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities laws of any
jurisdiction.

This communication may not be published, distributed or transmitted in or into
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People’s Republic of China, South Africa or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States of America or to U.S. persons (as defined in the U.S.
Securities Act of 1933, as amended (the “Securities Act”)) or to publications
with a general circulation in the United States of America. This document is not
an offer for sale of securities in the United States. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under
Securities Act. BerGenBio does not intend to register any part of the offering
in the United States. There will be no public offering of the securities in the
United States of America.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to
this communication in any member state of the European Economic Area (each an
“EEA Member State”) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable implementing
measures in any Member State, the “Prospectus Directive”) is only addressed to
qualified investors in that Member State within the meaning of the Prospectus
Directive. This announcement is not a prospectus within the meaning of the
Prospectus Directive, as implemented in each member State of the European
Economic Area. With respect to the EEA Member States, no action has been
undertaken or will be undertaken to make an offer to the public of the
securities referred to herein requiring a publication of a prospectus in any
Member State. As a result, the securities of the Company may not and will not be
offered in any Member State except in accordance with the exemptions set forth
in Article 3 of the Prospectus Directive.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of BerGenBio and those
explicitly or implicitly presumed in these statements. Against the background of
these uncertainties, readers should not rely on forward-looking statements.
BerGenBio assumes no responsibility to update forward -looking statements or to
adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Mykle]

Hmmmm. Vi vet Bemcentinib har blitt brukt mot Ebola. Med suksess.

[ezPappi]

Mot ebola og mot zika.
“Medisinen det er snakk om er den ikke-godkjente ebolamedisinen Remdesivir.”

[ListeBot]

En fersk aksjonærliste for BGBIO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis

[TekBot]

BerGenBio ASA: Annual general meeting

Bergen, Norway, 16 March 2020 - Annual general meeting of BerGenBio ASA was held
at Clarion Hotel Bergen Airport, Flyplassveien 551, 5869 Bergen, on 16 March
2020.
…

Vis børsmeldingen

All proposals were resolved as presented in the notice convening the annual
general meeting distributed on 24 February 2020, as further set out in the
minutes from the annual general meeting attached hereto and available at
https://www.bergenbio.com/investors/general-meetings/.

For further information, please contact:

Richard Godfrey

CEO, BerGenBio ASA

richard.godfrey@bergenbio.com

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Logdec]

Postet denne på PCIB tråden.
Ble veldig imponert når jeg tok et dykk inn i Bergenbio sine patenter og mulige fremtidige patenter.

———

Ref til min siste post over “In the Shoes of Investors”. Har hentet ut data fra forskjellige firma som viser antall patenter og publiseringer som er aktive.

PHO Patenter 30 Publiseringer 13

PCIB Patenter 11 Publiseringer 6

BGBIO Patenter 8 Publiseringer 8

Algeta Patenter 4 Publiseringer 4

TRVX Patenter 4 Publiseringer 0

ULTIMO Patenter 2 Publiseringer 0

NANO Patenter 2 Publiseringer 0

Publisering = avventer mulighet for patent

PHO har en miks av alt mulig – mye gammelt. Bergenbio har en fin miks med mye nytt. Algeta ble satt inn som referanse. Når det gjelder de to nederste på lista, så kan man jo si det slik: håper patentene er solide.
https://patents.justia.com/

[Ekornet]

Takk for informasjonen til deg Mr.!

[Ekornet]

Bergenbio opp 5,8 % kl 14.30, resten av biotek faller. Kommer det endelig tilsyne hvor mye av selskapet som er i langsiktige hender?

[ListeBot]

En fersk aksjonærliste for BGBIO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis

[sparkonge]

Er det noen som følger BGBIO tett som kan si noe om hvorfor Dominic Smethurst kun hadde stillingen som CMO i selskapet i tre måneder?

Interessant ettersom samme person nå er ansatt som interim CMO i NANO.

[ezPappi]

Ingen dramatikk. Dyktig fyr som fikk et bedre tilbud i NANO der han også ser masse potensiale.

[Mykle]

Han var bare interim i Bergen Bio. Hani Gabra som er cmo nå. Ingen smågutt dette…

Vice President in Early Clinical Development at AstraZeneca in Cambridge, UK, concurrently holding the positions of Professor of Medical Oncology at Imperial College London and Honorary Consultant in Medical Oncology at Imperial College Healthcare NHS Trust (since 2003) and Adjunct Professor at the Centre for Cancer Biomarkers at University of Bergen (since 2016). He was previously Head of Medical Oncology, Director of the Ovarian Cancer Action Research Centre and Head of Imperial College Cancer Clinical Trials Unit, as well as Chief of Service of the West London Gynaecological Cancer Centre at Imperial College London. Prior to that he was Cancer Research UK Clinical Scientist and Honorary Clinical Senior Lecturer/Consultant in Medical Oncology at the CRUK Medical Oncology Unit in the University of Edinburgh.

[William71]

Dette er mitt første innlegg noen sinne. Jeg er lege og mener st BerGenBio er det mest interessante selskapet på børs og kraftig undervurdert. Neppe noen på denne tråden som er uenige i det. Jeg synes at en spennende tanke er at AXL inhibitoren til BergenBio kanskje kunne ha noe for seg på Covid19. Det er jo mistenkelig stille fra selskapet . Alle de andre har vært ute med aksjonærmeldinger i forbindelse med kliniske studier osv , men ikke BergenBio såvidt jeg vet. Mulig jeg har oversett noe. Noen tanker der ute rundt dette?